A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Abstract
A first-in-human phase 1 clinical trial of the PEGylated protease-activated fluorescent probe, LUM015, enables tumor imaging at a safe and tolerable dose in humans.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 06, 2016
- Source ID
- 10.1126/scitranslmed.aad0293
Entities
People
- Alexander L. Lazarides
- Brian E. Brigman
- Chang-Lung Lee
- Dai Fukumura
- Dan G. Blazer Iii
- David B. Strasfeld
- David Kirsch
- Diana M Cardona
- E. Shelley Hwang
- Erin K. O'reilly
- Ivan Spasojevic
- Jeffrey K. Mito
- Joan Cahill
- Jorge M. Ferrer
- Kyle C. Cuneo
- Linda Griffith
- Matija Snuderl
- Melodi Javid Whitley
- Moungi Bawendi
- Nicole A. Larrier
- Paul J. Mosca
- Rachel A. Greenup
- Rakesh Jain
- Richard F. Riedel
- W. David Lee
- William C. Eward
Organizations
- American Society of Clinical Oncology
- Duke University
- Duke University Hospital
- Harvard Medical School
- Massachusetts Institute of Technology
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Institutes of Health